glp 1 serotonin Frontiers Frontiers | Exploring the multifaceted
Description
Disruptions in the supply of these critical inputs increase production lead times, delay product availability, elevate manufacturing costs, and constrain patient access to GLP-1 therapies across major global markets
Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al
This means the people most vulnerable to overdose are least able to seek this new treatment
Gene therapies (Luxturna for retinal dystrophy): Spark Therapeutics Luxturna (voretigene neparvovec) is a one-time gene therapy priced at $850,000 for both eyes in the U.S
